Drug profile · INN
iptacopan
FABHALTA
iptacopan (FABHALTA) is a complement factor b inhibitor. Associated with Novartis Pharmaceuticals.
EMA: approved TGA: approved Antineoplastic and immunomodulating agents (L04) L04A
Patents linked 0
Pipeline programs 15
News articles 0
Drug details — iptacopan
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- —
- Patents
- 0
- Programs
- 15
- Data quality
- 0.83
Quick answer
iptacopan (FABHALTA) is a complement factor b inhibitor. Associated with Novartis Pharmaceuticals.
Key facts
INN iptacopan
Brand FABHALTA
Mechanism Complement factor B inhibitor
Target Complement factor B
Therapeutic class Antineoplastic and immunomodulating agents (L04)
ATC code L04A
Originator Novartis Pharmaceuticals
Mechanism of action
Complement factor B inhibitor
Primary target: Complement factor B
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is iptacopan?
iptacopan (FABHALTA) is a complement factor b inhibitor. Associated with Novartis Pharmaceuticals.
What is the brand name for iptacopan?
FABHALTA is a marketed brand name for iptacopan. Check FDA Drugs@FDA for the current US label holder and prescribing information.